Leukemia: cord blood for allogeneic stem cell transplantation.

Leukemia: cord blood for allogeneic stem cell transplantation. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Leukemia: cord blood for allogeneic stem cell transplantation. Abstract Text:

Satoshi Takahashi,Satoshi Takahashi,

PURPOSE OF REVIEW: Cord blood is considered an acceptable alternative to hematopoietic stem cells. This review focuses on clinical results of cord blood transplantation including factors associated with transplantation outcomes for aiding graft selection. Immunological analysis of T cell recovery processes and approaches to cellular therapy using cord blood-derived immune cells are also discussed. RECENT FINDINGS: To resolve problems with cord blood transplantation, including high toxicity especially in the early phase after transplant and delayed engraftment, a reduced intensity regimen and double cord blood units from different donors are applied. For adequate graft selection, cell dose and human leukocyte antigen compatibility are important to reduce transplant-related toxicity, although the importance of human leukocyte antigen compatibility seems to disappear in leukemia patients because of a possible graft-versus-leukemia effect in a human leukocyte antigen-mismatched setting. Immune reconstitution after cord blood transplantation is also important to reduce the risk of infectious complication. Recent technologies make it possible to generate antigen-specific T cells from naïve T cells from cord blood in vitro. SUMMARY: Stem cell sources are now available for almost all leukemia patients. The efficacy of cord blood transplantation warrants further clarification by larger clinical experience and well designed studies. Efforts to reduce toxicity and improve engraftment are still in progress.

Leukemia: cord blood for allogeneic stem cell transplantation. Publishing Authors By Initials

S Takahashi,S Takahashi,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Leukemia: cord blood for allogeneic stem cell transplantation. Journal Published:

PUBLICATION TYPE: Review

Journal: Current opinion in oncology

VOLUME: 19

Page Numbers: 667-72

Journal Abbreviation:

ISSN: 1040-8746

DAY: 1

MONTH: Nov

YEAR: 2007

Leukemia: cord blood for allogeneic stem cell transplantation. Information

Number of References: 46

LANGUAGE: eng

NlmUniqueID: 9007265

Leukemia: cord blood for allogeneic stem cell transplantation. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Leukemia: cord blood for allogeneic stem cell transplantation. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Leukemia: cord blood for allogeneic stem cell transplantation.

AFFILIATION: Institute of Medical Science, University of Tokyo, Tokyo, Japan. radius@ims.u-tokyo.ac.jp

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Curr Opin Oncol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Leukemia: cord blood for allogeneic stem cell transplantation Related Publications

• A noncanonical E-box enhancer drives mouse Period2 circadian oscillations in vivo.
• Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-kappaB ligand.
• Circadian rhythms: the cancer connection.
• Comparison between stabilometry with and without head tilts in a roll plane.
• Effect of Escherichia coli wild type or its derivative with high nitrite reductase activity on in vitro ruminal methanogenesis and nitrate/nitrite reduction.
• Effect of gravity on apical dominance in Pharbitis nil.
• Effect of oral branched chain amino acid-rich nutrient administered during endoscopic injection sclerotherapy of cirrhotic patients.
• Forward genetic screens to identify circadian rhythm mutants in mice.
• Genome-wide epistatic interaction analysis reveals complex genetic determinants of circadian behavior in mice.
• Identification of the cDNA of differentially expressed genes in the transition zone of cucumber seedlings by fluorescent differential display.
• In vivo bone-forming capacity of human bone marrow-derived stromal cells is stimulated by recombinant human bone morphogenetic protein-2.
• Isolation of auxin efflux carrier cDNA from cucumber.
• Methods to record circadian rhythm wheel running activity in mice.
• Mice lacking smooth muscle calponin display increased bone formation that is associated with enhancement of bone morphogenetic protein responses.
• Mouse chimeras and their application to circadian biology.
• Novel hydrotropism mutants of Arabidopsis thaliana and their altered waving response and phototropism.
• Oral myiasis treated with ivermectin: case report.
• Osteoblasts provide a suitable microenvironment for the action of receptor activator of nuclear factor-kappaB ligand.
• Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption.
• Pax 2 expression in mesodermal segmentation and its relationship with EphA4 and Lunatic-fringe during chicken somitogenesis.
• Physiological and genetic characterization of hydrotropic mutants of Arabidopsis thaliana.
• Real-time luminescence reporting of circadian gene expression in mammals.
• Regulations: what next?
• The effect of light on the gravimorphogenesis of cucumber seedlings.
• The mouse Clock mutation reduces circadian pacemaker amplitude and enhances efficacy of resetting stimuli and phase-response curve amplitude.
• [Bone morphogenetic protein (BMP): from basic studies to clinical approaches]
• [Differential expression of a homing-related molecule repertoire among umbilical cord blood, mobilized peripheral blood and bone marrow-derived hematopoietic stem/progenitor cells.]
• [Gravitaxis of paramecium: testing the hypotheses by free-fall experiments]
• [Sequence variability in Borna disease virus ORF II from human beings]
• [The effects of space environment on differentiation and mutation frequency in Dictyostelium discoideum]